Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Zogenix (ZGNX) today and set a price target of $60. The company’s shares closed last Monday at $45.05.
According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -12.3% and a 29.9% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Achieve Life Sciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zogenix with a $64 average price target, a 42.2% upside from current levels. In a report released yesterday, Northland Securities also assigned a Buy rating to the stock with a $60 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $56.50 and a one-year low of $33.43. Currently, Zogenix has an average volume of 527.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.
